Subscribe
Bloomberg: Novartis Mulls Selling Its Ophthalmology Unit

Bloomberg: Novartis Mulls Selling Its Ophthalmology Unit

November 17, 2022

Novartis is considering selling its ophthalmology and respiratory units, a Bloomberg report said on Wednesday, citing people familiar with the matter.

According to the report, Novartis, which earlier this year announced a significant revamp that integrated its oncology and pharmaceuticals units, is still evaluating options for its ophthalmology and respiratory units. According to Bloomberg's sources, the ophthalmology sector might yield roughly $5 billion alone, and some private equity companies are already studying the businesses.

Novartis declined to comment on the matter at the time of publishing.

According to the restructuring plan unveiled in April, the ophthalmology and respiratory units do not come into the five main therapeutic areas that Novartis CEO Vas Narasimhan stated he is aiming for for the company's future. Those operations include hematology, immunology, solid tumors, neurology, and cardiovascular illnesses.

The Bloomberg report said any sales of the respiratory and ophthalmology businesses are likely to start in 2023, following Sandoz's planned separation as a generic and biosimilars company.

RELATED POSTS

Researchers Develop New Gene Therapy for Rare Ciliopathy
Researchers Develop New Gene Therapy for Rare Ciliopathy
1289 read
Genentech: Topline Phase 3 Results Show Vabysmo Improved Vision in People With RVO
Genentech: Topline Phase 3 Results Show Vabysmo Improved Vision in People With RVO
598 read
Novartis Agrees to Sell its Stake in Roche for $20.7 Billion, Parting Ways After 20 Years
Novartis Agrees to Sell its Stake in Roche for $20.7 Billion, Parting Ways After 20 Years
766 read
VSY Biotechnology’s Sinusoidal Vision Technology (SVT®) Secures U.S. Patent Grant
VSY Biotechnology’s Sinusoidal Vision Technology (SVT®) Secures U.S. Patent Grant
1291 read
Aldeyra Therapeutics Submits NDA for Reproxalap for Treatment of Signs and Symptoms of DED
Aldeyra Therapeutics Submits NDA for Reproxalap for Treatment of Signs and Symptoms of DED
1277 read
The World Council of Optometry and CooperVision Team Up to Release ‘A Practical Guide to Managing Children With Myopia’
The World Council of Optometry and CooperVision Team Up to Release ‘A Practical Guide to Managing Children With Myopia’
964 read
FCI Ophthalmics Announces FDA Clearance of Oculid Implantable and External Eyelid Weights for the Treatment of Lagophthalmos
FCI Ophthalmics Announces FDA Clearance of Oculid Implantable and External Eyelid Weights for the Treatment of Lagophthalmos
1111 read
Kiora Pharmaceuticals Granted Orphan Drug Designation for KIO-301, an Investigational Drug for the Treatment of Retinitis Pigmentosa
Kiora Pharmaceuticals Granted Orphan Drug Designation for KIO-301, an Investigational Drug for the Treatment of Retinitis Pigmentosa
596 read
EVMANN Takes Under its Umbrella Two Innovative, Fast-Growing Companies
EVMANN Takes Under its Umbrella Two Innovative, Fast-Growing Companies
1199 read
Pandemic Will Leave Children With Less Access To Eye Care
Pandemic Will Leave Children With Less Access To Eye Care
908 read